Tag: aids market forecast

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Expected Market Value Outlook For The Acquired Immunodeficiency Syndrome (AIDS) Market Through 2030?

The market size for acquired immunodeficiency syndrome (AIDS) has shown substantial growth in recent years. It is projected to expand from $33.75 billion in 2025 to $35.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.3%. This historical growth can be attributed to several factors, including the high prevalence of HIV infections worldwide, increasing awareness and screening programs, government-funded HIV treatment initiatives, the availability of first-generation antiretroviral drugs, and a rising incidence of opportunistic infections.

The market size for acquired immunodeficiency syndrome (aids) is expected to demonstrate robust growth in the coming years. It is projected to expand to $43.28 billion by 2030, achieving a compound annual growth rate (CAGR) of 5.1%. This anticipated expansion over the forecast period is driven by factors such as the development of advanced antiretroviral therapies, the widening reach of pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) initiatives, advancements in HIV vaccine research, the adoption of digital health monitoring systems, and an increase in public-private partnerships aimed at HIV management. Noteworthy trends during this period include the rising acceptance of antiretroviral therapy (ART), increased usage of pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), the broadening of HIV diagnostic and surveillance programs, an intensified focus on HIV vaccine research and development, and the integration of services across hospital and retail pharmacies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21076&type=smp

Which Drivers Are Advancing The Acquired Immunodeficiency Syndrome (AIDS) Market Growth?

Rising instances of HIV infections are anticipated to drive the expansion of the acquired immunodeficiency syndrome (AIDS) market in the future. HIV infections describe a state caused by the human immunodeficiency virus (HIV), which targets the immune system, thus diminishing the body’s capacity to combat infections and illnesses. The growing prevalence of HIV infections stems from factors such as unprotected sexual contact with an infected individual, the shared use of needles or syringes, exposure to tainted blood products, engaging with multiple sexual partners, and having a compromised immune system or pre-existing sexually transmitted infections. The management of acquired immunodeficiency syndrome (AIDS) supports patients with HIV infection through encouraging prompt diagnosis, broadening availability of potent antiretroviral treatments, improving preventive measures, and reinforcing healthcare infrastructures, all of which contribute to more effective containment of the virus’s dissemination. As an illustration, in November 2024, figures released by the European Centre for Disease Prevention and Control (ECDC), a Sweden-based European Union agency, indicated that 112,883 HIV diagnoses were registered in 2023 across 47 out of 53 regional countries, including 24,731 cases within the European Union/European Economic Area (EU/EEA). The collective crude rate of HIV diagnoses stood at 12.7 per 100,000 population, marking a 2.4% rise from the 12.4 per 100,000 rate noted in 2022. Consequently, the surge in HIV infections is a primary impetus for the acquired immunodeficiency syndrome (AIDS) market.

How Is The Acquired Immunodeficiency Syndrome (AIDS) Market Distributed Across Key Segments?

The acquired immunodeficiency syndrome (aids) market covered in this report is segmented –

1) By Type: Human Immunodeficiency Virus 1, Human Immunodeficiency Virus 2

2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion Inhibitors, CCR5 Anatagonists And Post-Attachment Inhibitors, Protease Inhibitors, Integrase Inhibitors, Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis

3) By Route Of Administration: Oral, Parenteral

4) By Application: Hospital Pharmacy, Retail Pharmacy, Other Applications

5) By Distribution Channel: Offline, Online

Subsegments:

1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), HIV-1 Diagnostic Tests, HIV-1 Vaccine Development, HIV-1 Opportunistic Infection Management

2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2, HIV-2 Diagnostic Tests, HIV-2 Surveillance And Epidemiology, HIV-2 Vaccine Research, Management Of HIV-2 Co-Infections

Which Trends Are Influencing The Direction Of The Acquired Immunodeficiency Syndrome (AIDS) Market?

Leading companies in the acquired immunodeficiency syndrome (AIDS) market are concentrating on the development of innovative therapies, such as long-acting injectables. These advancements aim to enhance patient compliance, lessen the frequency of administration, and offer a more convenient alternative to daily oral antiretroviral treatments. Long-acting injectables are medications delivered through injection, formulated to slowly release their active ingredients over an extended duration, which allows for less frequent dosing when compared to traditional oral medications. For example, in January 2025, GSK plc, a UK-based pharmaceutical company, announced that the European Commission had granted approval for its long-acting injectable treatment, Vocabria (cabotegravir) combined with Rekambys (rilpivirine). This treatment is approved for use in adolescents aged 12 years and older who are living with HIV. It is administered via intramuscular injection, typically either every one or two months, depending on the particular treatment plan. The prolonged action of these injections has the potential to improve adherence rates among adolescents who encounter difficulties with daily pill regimens.

Which Key Players Are Active In The Acquired Immunodeficiency Syndrome (AIDS) Market?

Major companies operating in the acquired immunodeficiency syndrome (aids) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy’s Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare

Access The Complete Acquired Immunodeficiency Syndrome (AIDS) Market Report:

https://www.thebusinessresearchcompany.com/report/acquired-immunodeficiency-syndrome-aids-global-market-report

Which Region Is The Primary Market For The Acquired Immunodeficiency Syndrome (AIDS) Market?

North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (aids) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Acquired Immunodeficiency Syndrome (AIDS) Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21076&type=smp

Browse Through More Reports Similar to the Global Acquired Immunodeficiency Syndrome (AIDS) Market 2026, By The Business Research Company

Acne Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/acne-drugs-global-market-report

Walking Aids Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/walking-aids-global-market-report

Immunoassay Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Expected Market Value Outlook For The Acquired Immunodeficiency Syndrome (AIDS) Market Through 2030?

The market size for acquired immunodeficiency syndrome (AIDS) has shown substantial growth in recent years. It is projected to expand from $33.75 billion in 2025 to $35.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.3%. This historical growth can be attributed to several factors, including the high prevalence of HIV infections worldwide, increasing awareness and screening programs, government-funded HIV treatment initiatives, the availability of first-generation antiretroviral drugs, and a rising incidence of opportunistic infections.

The market size for acquired immunodeficiency syndrome (aids) is expected to demonstrate robust growth in the coming years. It is projected to expand to $43.28 billion by 2030, achieving a compound annual growth rate (CAGR) of 5.1%. This anticipated expansion over the forecast period is driven by factors such as the development of advanced antiretroviral therapies, the widening reach of pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) initiatives, advancements in HIV vaccine research, the adoption of digital health monitoring systems, and an increase in public-private partnerships aimed at HIV management. Noteworthy trends during this period include the rising acceptance of antiretroviral therapy (ART), increased usage of pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), the broadening of HIV diagnostic and surveillance programs, an intensified focus on HIV vaccine research and development, and the integration of services across hospital and retail pharmacies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21076&type=smp

Which Drivers Are Advancing The Acquired Immunodeficiency Syndrome (AIDS) Market Growth?

Rising instances of HIV infections are anticipated to drive the expansion of the acquired immunodeficiency syndrome (AIDS) market in the future. HIV infections describe a state caused by the human immunodeficiency virus (HIV), which targets the immune system, thus diminishing the body’s capacity to combat infections and illnesses. The growing prevalence of HIV infections stems from factors such as unprotected sexual contact with an infected individual, the shared use of needles or syringes, exposure to tainted blood products, engaging with multiple sexual partners, and having a compromised immune system or pre-existing sexually transmitted infections. The management of acquired immunodeficiency syndrome (AIDS) supports patients with HIV infection through encouraging prompt diagnosis, broadening availability of potent antiretroviral treatments, improving preventive measures, and reinforcing healthcare infrastructures, all of which contribute to more effective containment of the virus’s dissemination. As an illustration, in November 2024, figures released by the European Centre for Disease Prevention and Control (ECDC), a Sweden-based European Union agency, indicated that 112,883 HIV diagnoses were registered in 2023 across 47 out of 53 regional countries, including 24,731 cases within the European Union/European Economic Area (EU/EEA). The collective crude rate of HIV diagnoses stood at 12.7 per 100,000 population, marking a 2.4% rise from the 12.4 per 100,000 rate noted in 2022. Consequently, the surge in HIV infections is a primary impetus for the acquired immunodeficiency syndrome (AIDS) market.

How Is The Acquired Immunodeficiency Syndrome (AIDS) Market Distributed Across Key Segments?

The acquired immunodeficiency syndrome (aids) market covered in this report is segmented –

1) By Type: Human Immunodeficiency Virus 1, Human Immunodeficiency Virus 2

2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion Inhibitors, CCR5 Anatagonists And Post-Attachment Inhibitors, Protease Inhibitors, Integrase Inhibitors, Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis

3) By Route Of Administration: Oral, Parenteral

4) By Application: Hospital Pharmacy, Retail Pharmacy, Other Applications

5) By Distribution Channel: Offline, Online

Subsegments:

1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), HIV-1 Diagnostic Tests, HIV-1 Vaccine Development, HIV-1 Opportunistic Infection Management

2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2, HIV-2 Diagnostic Tests, HIV-2 Surveillance And Epidemiology, HIV-2 Vaccine Research, Management Of HIV-2 Co-Infections

Which Trends Are Influencing The Direction Of The Acquired Immunodeficiency Syndrome (AIDS) Market?

Leading companies in the acquired immunodeficiency syndrome (AIDS) market are concentrating on the development of innovative therapies, such as long-acting injectables. These advancements aim to enhance patient compliance, lessen the frequency of administration, and offer a more convenient alternative to daily oral antiretroviral treatments. Long-acting injectables are medications delivered through injection, formulated to slowly release their active ingredients over an extended duration, which allows for less frequent dosing when compared to traditional oral medications. For example, in January 2025, GSK plc, a UK-based pharmaceutical company, announced that the European Commission had granted approval for its long-acting injectable treatment, Vocabria (cabotegravir) combined with Rekambys (rilpivirine). This treatment is approved for use in adolescents aged 12 years and older who are living with HIV. It is administered via intramuscular injection, typically either every one or two months, depending on the particular treatment plan. The prolonged action of these injections has the potential to improve adherence rates among adolescents who encounter difficulties with daily pill regimens.

Which Key Players Are Active In The Acquired Immunodeficiency Syndrome (AIDS) Market?

Major companies operating in the acquired immunodeficiency syndrome (aids) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy’s Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare

Access The Complete Acquired Immunodeficiency Syndrome (AIDS) Market Report:

https://www.thebusinessresearchcompany.com/report/acquired-immunodeficiency-syndrome-aids-global-market-report

Which Region Is The Primary Market For The Acquired Immunodeficiency Syndrome (AIDS) Market?

North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (aids) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Acquired Immunodeficiency Syndrome (AIDS) Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21076&type=smp

Browse Through More Reports Similar to the Global Acquired Immunodeficiency Syndrome (AIDS) Market 2026, By The Business Research Company

Acne Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/acne-drugs-global-market-report

Walking Aids Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/walking-aids-global-market-report

Immunoassay Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Acquired Immunodeficiency Syndrome (AIDS) Market Be By 2030 Compared To Its 2026 Market Size?

The market size for acquired immunodeficiency syndrome (aids) has shown substantial growth in recent years. It is forecast to expand from $33.75 billion in 2025 to $35.53 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.3%. Historically, this growth can be attributed to the significant worldwide prevalence of HIV infections, expanding awareness and screening initiatives, government-supported HIV treatment programs, the availability of first-generation antiretroviral drugs, and an escalating incidence of opportunistic infections.

The market size for acquired immunodeficiency syndrome (aids) is projected to undergo substantial expansion in the next few years. It is anticipated to reach $43.28 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 5.1%. This growth throughout the forecast period can be primarily attributed to the ongoing development of next-generation antiretroviral therapies, the expansion of PrEP and PEP programs, heightened research efforts for HIV vaccines, the increasing adoption of digital health monitoring solutions, and a rise in public-private partnerships aimed at HIV management. Significant trends expected during this forecast period encompass the increasing uptake of antiretroviral therapy (ART), a growing reliance on pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), the broadening of HIV diagnostic and surveillance programs, an intensified focus on HIV vaccine research and development, and the integration of services provided by hospital and retail pharmacies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/acquired-immunodeficiency-syndrome-aids-global-market-report

What Key Factors Are Shaping The Acquired Immunodeficiency Syndrome (AIDS) Market Landscape?

Rising instances of HIV infections are anticipated to boost the expansion of the acquired immunodeficiency syndrome (AIDS) market in the future. HIV infections describe a state triggered by the human immunodeficiency virus (HIV), which compromises the immune system, thereby diminishing the body’s capacity to combat infections and illnesses. The surge in HIV infection rates stems from factors such as unprotected sexual contact with an infected individual, the shared use of needles or syringes, exposure to tainted blood products, engaging with multiple sexual partners, and having a compromised immune system or pre-existing sexually transmitted infections. Management of acquired immunodeficiency syndrome (AIDS) supports patients with HIV infection by encouraging prompt diagnosis, broadening availability of potent antiretroviral treatments, improving prevention tactics, and reinforcing healthcare infrastructure, all of which aid in better managing the virus’s dissemination. As an illustration, data released in November 2024 by the European Centre for Disease Prevention and Control (ECDC), a Sweden-based European Union agency, indicated that 112,883 HIV diagnoses were documented in 2023 across 47 out of 53 regional countries, including 24,731 cases within the European Union/European Economic Area (EU/EEA). The total crude rate for HIV diagnoses reached 12.7 per 100,000 population, representing a 2.4% rise from the 12.4 per 100,000 rate noted in 2022. Consequently, the rising number of HIV infections is propelling the acquired immunodeficiency syndrome (AIDS) market.

Which Segment Categories Are Included In The Acquired Immunodeficiency Syndrome (AIDS) Market Segment Analysis?

The acquired immunodeficiency syndrome (aids) market covered in this report is segmented –

1) By Type: Human Immunodeficiency Virus 1, Human Immunodeficiency Virus 2

2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion Inhibitors, CCR5 Anatagonists And Post-Attachment Inhibitors, Protease Inhibitors, Integrase Inhibitors, Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis

3) By Route Of Administration: Oral, Parenteral

4) By Application: Hospital Pharmacy, Retail Pharmacy, Other Applications

5) By Distribution Channel: Offline, Online

Subsegments:

1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), HIV-1 Diagnostic Tests, HIV-1 Vaccine Development, HIV-1 Opportunistic Infection Management

2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2, HIV-2 Diagnostic Tests, HIV-2 Surveillance And Epidemiology, HIV-2 Vaccine Research, Management Of HIV-2 Co-Infections

What Market Trends Are Affecting The Acquired Immunodeficiency Syndrome (AIDS) Market?

Major companies engaged in the acquired immunodeficiency syndrome (AIDS) market are concentrating on creating novel therapies, such as long-acting injectables, which enhance patient adherence, decrease dosing frequency, and offer a more practical option than daily oral antiretroviral medications. Long-acting injectables are medications given by injection, designed to gradually release their active components over an extended period, allowing for less frequent administration compared to traditional oral drugs. As an illustration, in January 2025, the UK-based pharmaceutical company, GSK plc, declared that the European Commission had granted approval for its long-acting injectable treatment, Vocabria (cabotegravir) plus Rekambys (rilpivirine). This treatment is sanctioned for use in adolescents aged 12 years and older who are living with HIV, administered via intramuscular injection typically every one or two months, based on the specific treatment regimen. The extended duration of these injections has the potential to boost adherence among adolescents who find daily pill regimens challenging.

Who Are The Active Companies Shaping The Acquired Immunodeficiency Syndrome (AIDS) Market?

Major companies operating in the acquired immunodeficiency syndrome (aids) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy’s Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare

Get The Full Acquired Immunodeficiency Syndrome (AIDS) Market Report:

https://www.thebusinessresearchcompany.com/report/acquired-immunodeficiency-syndrome-aids-global-market-report

Which Geographic Region Dominates The Acquired Immunodeficiency Syndrome (AIDS) Market?

North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (aids) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Acquired Immunodeficiency Syndrome (AIDS) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/acquired-immunodeficiency-syndrome-aids-global-market-report

Browse Through More Reports Similar to the Global Acquired Immunodeficiency Syndrome (AIDS) Market 2026, By The Business Research Company

Immunoassay Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Acne Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/acne-drugs-global-market-report

Walking Aids Market Report 2026

https://www.thebusinessresearchcompany.com/report/walking-aids-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Acquired Immunodeficiency Syndrome (AIDS) Market During 2026–2030?

The market for acquired immunodeficiency syndrome (AIDS) has shown robust expansion over the past few years. Projections indicate it will expand from $33.75 billion in 2025 to $35.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.3%. This historical growth is linked to factors such as the widespread occurrence of HIV infections globally, enhanced awareness and screening efforts, government-backed HIV treatment programs, the introduction of early antiretroviral medications, and an increase in opportunistic infections.

The market for acquired immunodeficiency syndrome (aids) is projected to experience robust expansion over the coming years, reaching $43.28 billion by 2030, driven by a compound annual growth rate (CAGR) of 5.1%. This anticipated growth during the forecast period stems from factors such as the creation of advanced antiretroviral therapies, the broadening scope of prep and pep initiatives, progress in HIV vaccine investigations, the uptake of digital health monitoring tools, and an increase in collaborative public-private ventures for HIV management. Significant developments expected during this period involve a greater acceptance of antiretroviral therapy (ART), the increasing application of pre-exposure prophylaxis (prep) and post-exposure prophylaxis (pep), the enhancement of HIV diagnostic and surveillance frameworks, heightened emphasis on HIV vaccine research and development, and the merging of hospital and retail pharmacy services.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21076&type=smp

What Drivers Are Expected To Influence The Acquired Immunodeficiency Syndrome (AIDS) Market During The Forecast Period?

The acquired immunodeficiency syndrome (AIDS) market is anticipated to expand due to the increasing incidence of HIV infections. HIV infections characterize a condition caused by the human immunodeficiency virus (HIV), which targets the immune system, consequently diminishing the body’s capacity to combat infections and diseases. The escalating rates of HIV infections are attributed to various factors including unprotected sexual contact with an infected individual, sharing needles or syringes, receiving contaminated blood products, having multiple sexual partners, and a weakened immune system or pre-existing sexually transmitted infections. Managing acquired immunodeficiency syndrome (AIDS) supports HIV-infected patients by promoting early diagnosis, broadening access to effective antiretroviral therapies, strengthening prevention strategies, and improving healthcare systems, all of which contribute to better control over the virus’s dissemination. For instance, in November 2024, data published by the European Centre for Disease Prevention and Control (ECDC), a Sweden-based European Union agency, revealed that a total of 112,883 HIV diagnoses were reported in 2023 across 47 out of 53 countries in the region, with 24,731 cases specifically recorded in the European Union/European Economic Area (EU/EEA). The overall crude rate for HIV diagnoses reached 12.7 per 100,000 population, representing a 2.4% increase when compared to the 12.4 per 100,000 rate observed in 2022. Thus, the rise in HIV infections is propelling the acquired immunodeficiency syndrome (AIDS) market.

How Are The Various Segments Of The Acquired Immunodeficiency Syndrome (AIDS) Market Categorized?

The acquired immunodeficiency syndrome (aids) market covered in this report is segmented –

1) By Type: Human Immunodeficiency Virus 1, Human Immunodeficiency Virus 2

2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion Inhibitors, CCR5 Anatagonists And Post-Attachment Inhibitors, Protease Inhibitors, Integrase Inhibitors, Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis

3) By Route Of Administration: Oral, Parenteral

4) By Application: Hospital Pharmacy, Retail Pharmacy, Other Applications

5) By Distribution Channel: Offline, Online

Subsegments:

1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), HIV-1 Diagnostic Tests, HIV-1 Vaccine Development, HIV-1 Opportunistic Infection Management

2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2, HIV-2 Diagnostic Tests, HIV-2 Surveillance And Epidemiology, HIV-2 Vaccine Research, Management Of HIV-2 Co-Infections

What Trends Are Affecting The Expansion Of The Acquired Immunodeficiency Syndrome (AIDS) Market?

Leading companies within the acquired immunodeficiency syndrome (AIDS) market are prioritizing the development of innovative therapies, such as long-acting injectables. These advancements aim to improve patient compliance, reduce the frequency of administration, and offer a more convenient alternative to daily oral antiretroviral treatments. Long-acting injectables are medications given via injection, designed to slowly release their active ingredients over an extended period, thus allowing for less frequent dosing compared to traditional oral medications. For instance, in January 2025, GSK plc, a UK-based pharmaceutical company, announced that the European Commission had approved its long-acting injectable treatment, Vocabria (cabotegravir) plus Rekambys (rilpivirine). This treatment is approved for use in adolescents aged 12 years and older who are living with HIV. It is administered via intramuscular injection, typically every one or two months, depending on the specific treatment plan. The prolonged action of these injections may enhance adherence rates among adolescents who face challenges with daily pill regimens.

Which Major Firms Influence Developments In The Acquired Immunodeficiency Syndrome (AIDS) Market?

Major companies operating in the acquired immunodeficiency syndrome (aids) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy’s Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare

Read the full acquired immunodeficiency syndrome (aids) market report here:

https://www.thebusinessresearchcompany.com/report/acquired-immunodeficiency-syndrome-aids-global-market-report

Which Region Is Forecast To Lead The Acquired Immunodeficiency Syndrome (AIDS) Market In Terms Of Market Size?

North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (aids) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Acquired Immunodeficiency Syndrome (AIDS) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21076&type=smp

Browse Through More Reports Similar to the Global Acquired Immunodeficiency Syndrome (AIDS) Market 2026, By The Business Research Company

Acne Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/acne-drugs-global-market-report

walking aids global market report

https://www.thebusinessresearchcompany.com/report/walking-aids-global-market-report

immunoassay global market report

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Acquired Immunodeficiency Syndrome (AIDS) Market During 2026–2030?

The market for acquired immunodeficiency syndrome (AIDS) has shown robust expansion over the past few years. Projections indicate it will expand from $33.75 billion in 2025 to $35.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.3%. This historical growth is linked to factors such as the widespread occurrence of HIV infections globally, enhanced awareness and screening efforts, government-backed HIV treatment programs, the introduction of early antiretroviral medications, and an increase in opportunistic infections.

The market for acquired immunodeficiency syndrome (aids) is projected to experience robust expansion over the coming years, reaching $43.28 billion by 2030, driven by a compound annual growth rate (CAGR) of 5.1%. This anticipated growth during the forecast period stems from factors such as the creation of advanced antiretroviral therapies, the broadening scope of prep and pep initiatives, progress in HIV vaccine investigations, the uptake of digital health monitoring tools, and an increase in collaborative public-private ventures for HIV management. Significant developments expected during this period involve a greater acceptance of antiretroviral therapy (ART), the increasing application of pre-exposure prophylaxis (prep) and post-exposure prophylaxis (pep), the enhancement of HIV diagnostic and surveillance frameworks, heightened emphasis on HIV vaccine research and development, and the merging of hospital and retail pharmacy services.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21076&type=smp

What Drivers Are Expected To Influence The Acquired Immunodeficiency Syndrome (AIDS) Market During The Forecast Period?

The acquired immunodeficiency syndrome (AIDS) market is anticipated to expand due to the increasing incidence of HIV infections. HIV infections characterize a condition caused by the human immunodeficiency virus (HIV), which targets the immune system, consequently diminishing the body’s capacity to combat infections and diseases. The escalating rates of HIV infections are attributed to various factors including unprotected sexual contact with an infected individual, sharing needles or syringes, receiving contaminated blood products, having multiple sexual partners, and a weakened immune system or pre-existing sexually transmitted infections. Managing acquired immunodeficiency syndrome (AIDS) supports HIV-infected patients by promoting early diagnosis, broadening access to effective antiretroviral therapies, strengthening prevention strategies, and improving healthcare systems, all of which contribute to better control over the virus’s dissemination. For instance, in November 2024, data published by the European Centre for Disease Prevention and Control (ECDC), a Sweden-based European Union agency, revealed that a total of 112,883 HIV diagnoses were reported in 2023 across 47 out of 53 countries in the region, with 24,731 cases specifically recorded in the European Union/European Economic Area (EU/EEA). The overall crude rate for HIV diagnoses reached 12.7 per 100,000 population, representing a 2.4% increase when compared to the 12.4 per 100,000 rate observed in 2022. Thus, the rise in HIV infections is propelling the acquired immunodeficiency syndrome (AIDS) market.

How Are The Various Segments Of The Acquired Immunodeficiency Syndrome (AIDS) Market Categorized?

The acquired immunodeficiency syndrome (aids) market covered in this report is segmented –

1) By Type: Human Immunodeficiency Virus 1, Human Immunodeficiency Virus 2

2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion Inhibitors, CCR5 Anatagonists And Post-Attachment Inhibitors, Protease Inhibitors, Integrase Inhibitors, Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis

3) By Route Of Administration: Oral, Parenteral

4) By Application: Hospital Pharmacy, Retail Pharmacy, Other Applications

5) By Distribution Channel: Offline, Online

Subsegments:

1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), HIV-1 Diagnostic Tests, HIV-1 Vaccine Development, HIV-1 Opportunistic Infection Management

2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2, HIV-2 Diagnostic Tests, HIV-2 Surveillance And Epidemiology, HIV-2 Vaccine Research, Management Of HIV-2 Co-Infections

What Trends Are Affecting The Expansion Of The Acquired Immunodeficiency Syndrome (AIDS) Market?

Leading companies within the acquired immunodeficiency syndrome (AIDS) market are prioritizing the development of innovative therapies, such as long-acting injectables. These advancements aim to improve patient compliance, reduce the frequency of administration, and offer a more convenient alternative to daily oral antiretroviral treatments. Long-acting injectables are medications given via injection, designed to slowly release their active ingredients over an extended period, thus allowing for less frequent dosing compared to traditional oral medications. For instance, in January 2025, GSK plc, a UK-based pharmaceutical company, announced that the European Commission had approved its long-acting injectable treatment, Vocabria (cabotegravir) plus Rekambys (rilpivirine). This treatment is approved for use in adolescents aged 12 years and older who are living with HIV. It is administered via intramuscular injection, typically every one or two months, depending on the specific treatment plan. The prolonged action of these injections may enhance adherence rates among adolescents who face challenges with daily pill regimens.

Which Major Firms Influence Developments In The Acquired Immunodeficiency Syndrome (AIDS) Market?

Major companies operating in the acquired immunodeficiency syndrome (aids) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy’s Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare

Read the full acquired immunodeficiency syndrome (aids) market report here:

https://www.thebusinessresearchcompany.com/report/acquired-immunodeficiency-syndrome-aids-global-market-report

Which Region Is Forecast To Lead The Acquired Immunodeficiency Syndrome (AIDS) Market In Terms Of Market Size?

North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (aids) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Acquired Immunodeficiency Syndrome (AIDS) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21076&type=smp

Browse Through More Reports Similar to the Global Acquired Immunodeficiency Syndrome (AIDS) Market 2026, By The Business Research Company

Acne Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/acne-drugs-global-market-report

walking aids global market report

https://www.thebusinessresearchcompany.com/report/walking-aids-global-market-report

immunoassay global market report

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model